Biomarker-based Bayesian randomized phase II clinical trial design to identify a sensitive patient subpopulation

Statistics in Medicine

Volumn 33, Issue 23, 2014, Pages 4008-4016

  Morita, Satoshi ^a   Yamamoto, Hideharu ^b   Sugitani, Yasuo ^b  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Bayesian statistics; biomarker; molecular targeted agent; randomized phase II trial; time to event data

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BAYES THEOREM; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; COMPARATIVE STUDY; DRUG EFFICACY; EVALUATION STUDY; HAZARD RATIO; HUMAN; LIVER CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PROBABILITY; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; REGRESSION ANALYSIS; SIMULATION; STUDY DESIGN; SURVIVAL TIME;

EID: 84999978759     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.6209     Document Type: Article

References (23)

1. Simon R, Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clinical Cancer Research 2004; 10: 6759–6763.
2. Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, Le Blanc M, Stewart D, Crowley J, Groshen S, Humphrey JS, West P, Berry D. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clinical Cancer Research 2010; 16: 1764–1769.
3. McShane LM, Hunsberger S, Adjei AA. Effective incorporation of biomarkers into phase II trials. Clinical Cancer Research 2009; 15: 1898–1905.
4. Dancey JE, Dobbin KK, Groshen S, Jessup JM, Hruszkewycz AH, Koehler M, Parchment R, Ratain MJ, Shankar LK, Stadler WM, True LD, Gravell A, Grever MR, Biomarkers Task Force of the NCI Investigational Drug Steering Committee. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clinical Cancer Research 2010; 16: 1745–1755.
5. Parmar MK, Barthel FM, Sydes M, Langley R, Kaplan R, Eisenhauer E, Brady M, James N, Bookman MA, Swart AM, Qian W, Royston P. Speeding up the evaluation of new agents in cancer. Journal of the National Cancer Institute 2008; 100: 1204–1214.
6. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: one size does not fit all. Journal Of Biopharmaceutical Statistics 2009; 19: 530–542.
7. Buyse M, Michiels S, Sargent DJ, Grothey A, Matheson A, de Gramont A. Integrating biomarkers in clinical trials. Expert Review of Molecular Diagnostics 2011; 11: 171–182.
8. Baselga J. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology 2001; 61(Suppl 2):14–21.
9. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology 2008; 26: 1626–1634.
10. Jiang W, Freidlin B, Simon R. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. Journal of the National Cancer Institute 2007; 99: 1036–1043.
11. Yin G. Clinical Trial Design: Bayesian and Frequentist Adaptive Methods. Wiley: Hoboken, 2012.
12. Wang SJ, O'Neill RT, Hung HM. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharmaceutical Statistics 2007; 6: 227–244.
13. Brannath W, Zuber E, Branson M, Bretz F, Gallo P, Posch M, Racine-Poon A. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology. Statistics in Medicine 2009; 28: 1445–1463.
14. Eickhoff JC, Kim K, Beach J, Kolesar JM, Gee JR. A Bayesian adaptive design with biomarkers for targeted therapies. Clinical Trials 2010; 7: 546–556.
15. Jenkins M, Stone A, Jennison C. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints. Pharmaceutical Statistics 2011; 10: 347–356.
16. Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC. Clinical trial designs for cytostatic agents: are new approaches needed? Journal of Clinical Oncology 2001; 19: 265–272.
17. Sinha D, Ibrahim JG, Chen MH. A Bayesian justification of Cox's partial likelihood. Biometrika 2003; 90: 629–641.
18. Ibrahim JG, Chen MH, Sinha D. Bayesian survival analysis. In Encyclopedia of Biostatistics, Armitage P, Colton T (eds). John Wiley and Sons: Chichester, 2005; 352–366.
19. Gilks W, Richardson S, Spiegelhalter D. Markov Chain Monte Carlo in Practice, Chapman & Hall: London, 1996.
20. US Food and Drug Administration (USFDA). Guidance on Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products, US FDA: Rockville, MD, 2012.
21. Llovet JM, Pena CE, Lathia CD, Shan M, Meinhardt G, Bruix J, SHARP Investigators Study Group. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clinical Cancer Research 2012; 18: 2290–2300.
22. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine 2008; 359: 378–390.
23. Yuan Y, Yin G. Dose–response curve estimation: a semiparametric mixture approach. Biometrics 2011; 67: 1543–1554.